Literature DB >> 25576859

Guanylate cyclase C agonists: emerging gastrointestinal therapies and actions.

Michael Camilleri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25576859     DOI： 10.1053/j.gastro.2015.01.003

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  18 in total

1.  Understanding and Managing IBS and CIC in the Primary Care Setting.

Authors:  Brooks D Cash
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

2.  GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.

Authors:  Peng Li; Evan Wuthrick; Jeff A Rappaport; Crystal Kraft; Jieru E Lin; Glen Marszalowicz; Adam E Snook; Tingting Zhan; Terry M Hyslop; Scott A Waldman
Journal:  Cancer Res       Date:  2017-09-15       Impact factor: 12.701

3.  Linaclotide Attenuates Visceral Organ Crosstalk: Role of Guanylate Cyclase-C Activation in Reversing Bladder-Colon Cross-Sensitization.

Authors:  Ehsan N Mohammadi; Casey O Ligon; Ada Silos-Santiago; Pei Ge; Caroline Kurtz; Carolyn Higgins; Gerhard Hannig; Beverley Greenwood-Van Meerveld
Journal:  J Pharmacol Exp Ther       Date:  2018-05-21       Impact factor: 4.030

Review 4.  Update on the Management of Chronic Constipation.

Authors:  Jenna Koliani-Pace; Brian E Lacy
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

Review 5.  Diagnosis and management of chronic constipation in adults.

Authors:  Satish S C Rao; Kulthep Rattanakovit; Tanisa Patcharatrakul
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-01       Impact factor: 46.802

6.  The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease.

Authors:  Øystein Brenna; Torunn Bruland; Marianne W Furnes; Atle van Beelen Granlund; Ignat Drozdov; Johanna Emgård; Gunnar Brønstad; Mark Kidd; Arne K Sandvik; Björn I Gustafsson
Journal:  Scand J Gastroenterol       Date:  2015-05-15       Impact factor: 2.423

7.  Congenital secretory diarrhoea caused by activating germline mutations in GUCY2C.

Authors:  Thomas Müller; Insha Rasool; Peter Heinz-Erian; Eva Mildenberger; Christian Hülstrunk; Andreas Müller; Laurent Michaud; Bart G P Koot; Antje Ballauff; Julia Vodopiutz; Stefan Rosipal; Britt-Sabina Petersen; Andre Franke; Irene Fuchs; Heiko Witt; Heinz Zoller; Andreas R Janecke; Sandhya S Visweswariah
Journal:  Gut       Date:  2015-05-20       Impact factor: 23.059

8.  Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.

Authors:  Michael DeMicco; Laura Barrow; Bernadette Hickey; Kunwar Shailubhai; Patrick Griffin
Journal:  Therap Adv Gastroenterol       Date:  2017-10-25       Impact factor: 4.409

9.  Expression of guanylate cyclase-C, guanylin, and uroguanylin is downregulated proportionally to the ulcerative colitis disease activity index.

Authors:  Danfeng Lan; Junkun Niu; Jiarong Miao; Xiangqian Dong; Hong Wang; Gang Yang; Kunhua Wang; Yinglei Miao
Journal:  Sci Rep       Date:  2016-04-29       Impact factor: 4.379

10.  CFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipation.

Authors:  Onur Cil; Puay-Wah Phuan; Sujin Lee; Joseph Tan; Peter M Haggie; Marc H Levin; Liang Sun; Jay R Thiagarajah; Tonghui Ma; A S Verkman
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.